{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.045","upperLimit":"0.361","value":"0.16"},{"groupId":"OG001","lowerLimit":"0.010","upperLimit":"0.251","value":"0.08"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"description":"Will be assessed by computed tomography (CT)-based criteria or positron emission tomography (PET)-CT based criteria. A response will be defined as an objective status of partial remission (PR) or complete remission (CR) for patients evaluated by CT-based criteria and complete metabolic response (CMR) or partial metabolic response (PMR) for patients evaluated by PET-CT based criteria. Exact binomial ninety-five percent confidence intervals for the true success proportion will be calculated in each arm. Comparison of overall response rates between the two treatment groups will be performed using a one-sided Fisher's exact test at significance level 0.15.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may cross over to Group II at the time of disease progression.","id":"OG000","title":"Group I (Nivolumab)"},{"description":"Patients receive varlilumab IV over 90 minutes every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also receive nivolumab IV over 30 minutes every 2 weeks for 4 months and every 4 weeks for a total of up to 2 years in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Group II (Varlilumab, Nivolumab)"}],"paramType":"NUMBER","populationDescription":"All eligible patients that had a disease evaluation after being treated.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Overall Response Rate","type":"PRIMARY","unitOfMeasure":"proportion of participants"}